Ero1a, the most strongly hypoxia-induced protein in PASMCs, promotes the development of hypoxia- and monocrotaline-induced pulmonary hypertension in rats
Life Sciences · 2025
DOI: 10.1016/j.lfs.2025.123754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2025. Verfasst von Xiaojun Hao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Pulmonary Artery, Myocytes, Smooth Muscle, Hypoxia. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Wuhan University, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
AIMS: Pulmonary hypertension (PH) is a progressive and life-threatening condition characterized by elevated pressure in the pulmonary circulation, leading to right heart dysfunction and ultimately heart failure. Pulmonary artery smooth muscle cells (PASMCs) are key players in group 3 PH (due to lung diseases and/or hypoxia) progression, where their aberrant proliferation and migration drive vascular remodeling. Dysregulated proteins in PASMCs are critical in PH development. Our research was designed to investigate the most promising potential therapeutic targets for PH. MATERIALS AND METHODS: Proteomics was used to identify the most significantly upregulated protein in PASMCs under hypoxia. siRNA or plasmid transfection was used to silence or overexpress Ero1a. The proliferation, migration, and apoptosis of PASMCs were assessed respectively. Both hypoxia and monocrotaline-induced pulmonary hypertension model were established in animals. The expression of Ero1a was reduced to explore its role in PH. Bioinformatic analysis were conducted to investigate the signaling pathways involved in the disease progression. KEY FINDINGS: Ero1a was confirmed as the most significantly upregulated protein in PASMCs under hypoxia. Silencing Ero1a reduced PASMC proliferation, migration, and apoptosis resistance under both normoxic and hypoxic conditions, while overexpression of Ero1a had the opposite effect. Exposure of rats to hypoxia, along with intraperitoneal injection of MCT solution, induced PH. However, knockdown of Ero1a alleviated all these pathological features. The HIF1-Ero1a-Apelin/APJ signaling axis was speculated to mediate the functional role of Ero1a in PH. SIGNIFICANCE: Our study identifies that targeting Ero1a may represent a promising therapeutic strategy for pulmonary hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
- Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, Chi…
- Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Electronic address: Jianghx@whu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Wuhan University
- Fundamental Research Funds for the Central Universities
- Zhongnan Hospital of Wuhan University
Zitieren
APA
Hao, X., Li, H., Zeng, Q., Cheng, Z., & Jiang, H. (2025). Ero1a, the most strongly hypoxia-induced protein in PASMCs, promotes the development of hypoxia- and monocrotaline-induced pulmonary hypertension in rats. Life Sciences. https://doi.org/10.1016/j.lfs.2025.123754
Vancouver
Hao X, Li H, Zeng Q, Cheng Z, Jiang H. Ero1a, the most strongly hypoxia-induced protein in PASMCs, promotes the development of hypoxia- and monocrotaline-induced pulmonary hypertension in rats. Life Sciences. 2025. doi:10.1016/j.lfs.2025.123754
BibTeX
@article{Hao2025,
author = {Hao, Xiaojun and Li, Hao and Zeng, Qingli and Cheng, Zhenshun and Jiang, Hongxia},
title = {Ero1a, the most strongly hypoxia-induced protein in PASMCs, promotes the development of hypoxia- and monocrotaline-induced pulmonary hypertension in rats},
journal = {Life Sciences},
year = {2025},
doi = {10.1016/j.lfs.2025.123754}
}
EUVIMED